Emma J Mew1, Andrea Monsour1, Leena Saeed1, Lucia Santos1, Sagar Patel1, Darren B Courtney2, Priya N Watson2, Peter Szatmari3, Martin Offringa4, Suneeta Monga5, Nancy J Butcher6. 1. Child Health Evaluative Sciences, The Hospital for Sick Children Research Institute, Toronto, Ontario, Canada. 2. Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada. 3. Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada; Department of Psychiatry, The Hospital for Sick Children, Toronto, Ontario, Canada. 4. Child Health Evaluative Sciences, The Hospital for Sick Children Research Institute, Toronto, Ontario, Canada; Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada; Division of Neonatology, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada. Electronic address: martin.offringa@sickkids.ca. 5. Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada; Department of Psychiatry, The Hospital for Sick Children, Toronto, Ontario, Canada. 6. Child Health Evaluative Sciences, The Hospital for Sick Children Research Institute, Toronto, Ontario, Canada. Electronic address: nancy.butcher@sickkids.ca.
Abstract
OBJECTIVES: The objective of this review was to identify outcomes reported in adolescent major depressive disorder trials and quantify outcome heterogeneity. STUDY DESIGN AND SETTING: Three databases were searched to identify trials evaluating therapies for major depressive disorder in adolescents published from 2008 to 2017. Identified outcomes were thematically grouped and mapped into predefined outcome core areas (physiological/clinical, life impact, resource use, adverse events, and death). Outcome heterogeneity was quantified using descriptive analyses. RESULTS: Of 2,686 articles yielded from the search, 42 articles describing 32 trials were included. A total of 434 outcomes measured using 118 different outcome measurement instruments were grouped into 86 unique outcome terms. Most outcome terms mapped to the physiological/clinical core area (62%), followed by the life impact (27%). Nearly half (45%) were reported in only a single trial each. Of 18 primary outcomes reported, 13 (72%) were each only reported in a single trial. "Depressive symptom severity", reported in 30 trials (94%), was measured using 19 different outcome measurement instruments. CONCLUSION: Heterogeneity exists in the outcomes and outcome measurement instruments used in adolescent depression trials. To enable reproducibility, comparison, and synthesis of trial results, a standard set of agreed-on outcomes and methods of measurement is needed.
OBJECTIVES: The objective of this review was to identify outcomes reported in adolescent major depressive disorder trials and quantify outcome heterogeneity. STUDY DESIGN AND SETTING: Three databases were searched to identify trials evaluating therapies for major depressive disorder in adolescents published from 2008 to 2017. Identified outcomes were thematically grouped and mapped into predefined outcome core areas (physiological/clinical, life impact, resource use, adverse events, and death). Outcome heterogeneity was quantified using descriptive analyses. RESULTS: Of 2,686 articles yielded from the search, 42 articles describing 32 trials were included. A total of 434 outcomes measured using 118 different outcome measurement instruments were grouped into 86 unique outcome terms. Most outcome terms mapped to the physiological/clinical core area (62%), followed by the life impact (27%). Nearly half (45%) were reported in only a single trial each. Of 18 primary outcomes reported, 13 (72%) were each only reported in a single trial. "Depressive symptom severity", reported in 30 trials (94%), was measured using 19 different outcome measurement instruments. CONCLUSION: Heterogeneity exists in the outcomes and outcome measurement instruments used in adolescent depression trials. To enable reproducibility, comparison, and synthesis of trial results, a standard set of agreed-on outcomes and methods of measurement is needed.
Authors: Pedro H Manfro; Rivka B Pereira; Martha Rosa; Hugo Cogo-Moreira; Helen L Fisher; Brandon A Kohrt; Valeria Mondelli; Christian Kieling Journal: Eur Child Adolesc Psychiatry Date: 2021-12-02 Impact factor: 4.785
Authors: Ellen B M Elsman; Nancy J Butcher; Lidwine B Mokkink; Caroline B Terwee; Andrea Tricco; Joel J Gagnier; Olalekan Lee Aiyegbusi; Carolina Barnett; Maureen Smith; David Moher; Martin Offringa Journal: Syst Rev Date: 2022-06-13
Authors: Kun Qin; Du Lei; Jing Yang; Wenbin Li; Maxwell J Tallman; Luis Rodrigo Patino Duran; Thomas J Blom; Kaitlyn M Bruns; Sian Cotton; John A Sweeney; Qiyong Gong; Melissa P DelBello Journal: BMC Psychiatry Date: 2021-04-28 Impact factor: 3.630